Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Acurx Pharmaceuticals, Inc. (ACXP) stock rallied over 5.41% intraday to trade at $3.70 a share on NASDAQ. The stock opened with a gain of 1.93% at $3.48 and touched an intraday high of $3.762, rising 5.41% against the last close of $3.51. The stock went to a low of $3.47 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $3.48 | $3.762 | $3.47 | $3.7 | 30,576 |
2022-07-05 | $3.63 | $3.72 | $3.44 | $3.51 | 26,400 |
2022-07-01 | $3.82 | $3.82 | $3.628 | $3.75 | 10,500 |
2022-06-30 | $3.63 | $3.83 | $3.52 | $3.79 | 27,700 |
2022-06-29 | $3.85 | $3.91 | $3.62 | $3.63 | 30,600 |
2022-06-28 | $3.76 | $3.83 | $3.69 | $3.8 | 3,500 |
2022-06-27 | $3.82 | $3.82 | $3.65 | $3.7 | 4,800 |
2022-06-24 | $3.61 | $3.76 | $3.606 | $3.69 | 6,300 |
2022-06-23 | $3.51 | $3.6 | $3.51 | $3.55 | 1,300 |
2022-06-22 | $3.62 | $3.63 | $3.5 | $3.62 | 7,700 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) stock price is $3.7 as of the last check on Wednesday, July 6. During the trading session, ACXP stock reached the peak price of $3.762 while $3.47 was the lowest point it dropped to.
The NASDAQ listed ACXP is part of Biotechnology industry that operates in the broader Health Care sector. Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
Mr. David P. Luci CPA, CPA, J.D., Esq.
Co-Founder, Pres, CEO & Director
Mr. Robert J. DeLuccia
Co-Founder & Exec. Chairman
Mr. David P. Luci CPA, CPA, Esq., J.D.
Corp. Sec., Co-Founder, Pres, CEO & Director
Mr. Robert G. Shawah CPA
Co-Founder & CFO
ACXP stock traded closed the last session at $3.7, which is $0.19 or 5.41% lower than its previous close of $3.51. ACXP's current trading price is 58.79% lower than its 52-week high of $6.35 where as its distance from 52-week low of 2.33% is -41.73%.
Number of ACXP employees currently stands at -. ACXP operates from 259 Liberty Avenue, Staten Island, NY 10305, United States.
Official Webiste of $ACXP is: https://www.acurxpharma.com
ACXP could be contacted at ACXP operates from 259 Liberty Avenue, Staten Island, NY 10305, United States, or at phone #917-533-1469 and can also be accessed through its website.
ACXP stock volume for the day was 30,576 shares while in the previous session number of ACXP shares traded was 30,576 . The average number of ACXP shares traded daily for last 3 months was 16.19 Thousands.
The percentage change in ACXP stock occurred in the recent session was 5.41% while the dollar amount for the price change in ACXP stock was $0.19.
In the recent session, the day high for ACXP stock was $3.762 while the low for ACXP stock touched on the day was $3.47.
The market value of ACXP currently stands at 38.37 Million with its latest stock price at $3.7 and 10.23 Million of its shares outstanding.